Sign up now with your company or organization email and enjoy a
1-week free trial!
Contract Details
| Title |
Hereditary Angioedema United Kingdom |
|||
|---|---|---|---|---|
You can sign up and unlock it for freeAccess to Public and Private Sector Business Opportunities for 200+ Countries |
||||
| Country | ||||
| Language | English | |||
| Organization | ||||
| Published Date | 31.03.2024 | |||
| Awarded Date | 19.07.2022 | |||
| Overview | Contract Award's Details : Hereditary Angioedema NHS England Hereditary Angioedema NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority& 039;s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months United Kingdom Contract value : 74,500,000.00 GBP Contractors : Accord-UK Ltd, Wockhardt UK Limited, CSL Behring UK Ltd, Takeda UK Ltd, Martindale Pharma, Piramal Critical care Limited, Cipla, BioCryst Ireland Limited, Pharming Group, Celix Pharma Ltd. 20/06/2022 20/07/2022 31/12/2023 78476970 20/07/2022 NHS England Address : 2nd Floor, Rutland House WA7 2ES, Runcorn Philip Grieve philip.grieve@nhs.net United Kingdom United Kingdom Contract Awards United Kingdom ocds-b5fd17-5242c430-9651-453d-9ccd-71a66de32b6f-556317-cf-0980900d0o000000rwimuaa1 20/06/2022 31/12/2023 74,500,000.00 GBP | |||
| NAICS | ||||
| CPVS |
-
|
|||
| UNSPSC |
-
|
|||
| Regions | ||||
| Sectors | ||||
| Contractor | ||||
| Contract Value |
74,500,000.00 GBP
|
URL | ||
| Share | ||||
United Kingdom
| Title |
|---|
Hereditary Angioedema United Kingdom |
| Country |
| Language |
| English |
| Organization |
| Published Date |
| 31.03.2024 |
| Awarded Date |
| 19.07.2022 |
| Overview |
| Contract Award's Details : Hereditary Angioedema NHS England Hereditary Angioedema NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority& 039;s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months United Kingdom Contract value : 74,500,000.00 GBP Contractors : Accord-UK Ltd, Wockhardt UK Limited, CSL Behring UK Ltd, Takeda UK Ltd, Martindale Pharma, Piramal Critical care Limited, Cipla, BioCryst Ireland Limited, Pharming Group, Celix Pharma Ltd. 20/06/2022 20/07/2022 31/12/2023 78476970 20/07/2022 NHS England Address : 2nd Floor, Rutland House WA7 2ES, Runcorn Philip Grieve philip.grieve@nhs.net United Kingdom United Kingdom Contract Awards United Kingdom ocds-b5fd17-5242c430-9651-453d-9ccd-71a66de32b6f-556317-cf-0980900d0o000000rwimuaa1 20/06/2022 31/12/2023 74,500,000.00 GBP |
| NAICS |
| Management |
| CPVS |
| - |
| UNSPSC |
| - |
| Regions |
| Europe Northern Europe |
| Sectors |
| Automobiles and Auto Parts Non-Renewable Energy Supply Railways-Rail-Railroad Defence and Security Electricity Construction Energy-Power and Electrical Computer Hardwares and Consumables Marine |
| Contractor |
| Contract Value |
|
74,500,000.00 GBP
|
| URL |
|
|
| Share |
To be notified
when a tender matching your filter is
published
To Follow
Tenders
Add New Tender Alert
To Follow
Contracts
Add New Contract Alert
To Follow
Fairs
Add New Fair Alert
Similar Contracts